Cargando…

Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis

OBJECTIVE: To describe the development and validation of a novel patient reported outcome measure for symptom burden from long covid, the symptom burden questionnaire for long covid (SBQ-LC). DESIGN: Multiphase, prospective mixed methods study. SETTING: Remote data collection and social media channe...

Descripción completa

Detalles Bibliográficos
Autores principales: Hughes, Sarah E, Haroon, Shamil, Subramanian, Anuradhaa, McMullan, Christel, Aiyegbusi, Olalekan L, Turner, Grace M, Jackson, Louise, Davies, Elin Haf, Frost, Chris, McNamara, Gary, Price, Gary, Matthews, Karen, Camaradou, Jennifer, Ormerod, Jane, Walker, Anita, Calvert, Melanie J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043395/
https://www.ncbi.nlm.nih.gov/pubmed/35477524
http://dx.doi.org/10.1136/bmj-2022-070230
_version_ 1784694868892712960
author Hughes, Sarah E
Haroon, Shamil
Subramanian, Anuradhaa
McMullan, Christel
Aiyegbusi, Olalekan L
Turner, Grace M
Jackson, Louise
Davies, Elin Haf
Frost, Chris
McNamara, Gary
Price, Gary
Matthews, Karen
Camaradou, Jennifer
Ormerod, Jane
Walker, Anita
Calvert, Melanie J
author_facet Hughes, Sarah E
Haroon, Shamil
Subramanian, Anuradhaa
McMullan, Christel
Aiyegbusi, Olalekan L
Turner, Grace M
Jackson, Louise
Davies, Elin Haf
Frost, Chris
McNamara, Gary
Price, Gary
Matthews, Karen
Camaradou, Jennifer
Ormerod, Jane
Walker, Anita
Calvert, Melanie J
author_sort Hughes, Sarah E
collection PubMed
description OBJECTIVE: To describe the development and validation of a novel patient reported outcome measure for symptom burden from long covid, the symptom burden questionnaire for long covid (SBQ-LC). DESIGN: Multiphase, prospective mixed methods study. SETTING: Remote data collection and social media channels in the United Kingdom, 14 April to 1 August 2021. PARTICIPANTS: 13 adults (aged ≥18 years) with self-reported long covid and 10 clinicians evaluated content validity. 274 adults with long covid field tested the draft questionnaire. MAIN OUTCOME MEASURES: Published systematic reviews informed development of SBQ-LC’s conceptual framework and initial item pool. Thematic analysis of transcripts from cognitive debriefing interviews and online clinician surveys established content validity. Consensus discussions with the patient and public involvement group of the Therapies for Long COVID in non-hospitalised individuals: From symptoms, patient reported outcomes and immunology to targeted therapies (TLC Study) confirmed face validity. Rasch analysis of field test data guided item and scale refinement and provided initial evidence of the SBQ-LC’s measurement properties. RESULTS: SBQ-LC (version 1.0) is a modular instrument measuring patient reported outcomes and is composed of 17 independent scales with promising psychometric properties. Respondents rate their symptom burden during the past seven days using a dichotomous response or 4 point rating scale. Each scale provides coverage of a different symptom domain and returns a summed raw score that can be transformed to a linear (0-100) score. Higher scores represent higher symptom burden. After rating scale refinement and item reduction, all scales satisfied the Rasch model requirements for unidimensionality (principal component analysis of residuals: first residual contrast values <2.00 eigenvalue units) and item fit (outfit mean square values within 0.5 -1.5 logits). Rating scale categories were ordered with acceptable category fit statistics (outfit mean square values <2.0 logits). 14 item pairs had evidence of local dependency (residual correlation values >0.4). Across the 17 scales, person reliability ranged from 0.34 to 0.87, person separation ranged from 0.71 to 2.56, item separation ranged from 1.34 to 13.86, and internal consistency reliability (Cronbach’s alpha) ranged from 0.56 to 0.91. CONCLUSIONS: SBQ-LC (version 1.0) is a comprehensive patient reported outcome instrument developed using modern psychometric methods. It measures symptoms of long covid important to people with lived experience of the condition and may be used to evaluate the impact of interventions and inform best practice in clinical management.
format Online
Article
Text
id pubmed-9043395
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-90433952022-04-27 Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis Hughes, Sarah E Haroon, Shamil Subramanian, Anuradhaa McMullan, Christel Aiyegbusi, Olalekan L Turner, Grace M Jackson, Louise Davies, Elin Haf Frost, Chris McNamara, Gary Price, Gary Matthews, Karen Camaradou, Jennifer Ormerod, Jane Walker, Anita Calvert, Melanie J BMJ Research OBJECTIVE: To describe the development and validation of a novel patient reported outcome measure for symptom burden from long covid, the symptom burden questionnaire for long covid (SBQ-LC). DESIGN: Multiphase, prospective mixed methods study. SETTING: Remote data collection and social media channels in the United Kingdom, 14 April to 1 August 2021. PARTICIPANTS: 13 adults (aged ≥18 years) with self-reported long covid and 10 clinicians evaluated content validity. 274 adults with long covid field tested the draft questionnaire. MAIN OUTCOME MEASURES: Published systematic reviews informed development of SBQ-LC’s conceptual framework and initial item pool. Thematic analysis of transcripts from cognitive debriefing interviews and online clinician surveys established content validity. Consensus discussions with the patient and public involvement group of the Therapies for Long COVID in non-hospitalised individuals: From symptoms, patient reported outcomes and immunology to targeted therapies (TLC Study) confirmed face validity. Rasch analysis of field test data guided item and scale refinement and provided initial evidence of the SBQ-LC’s measurement properties. RESULTS: SBQ-LC (version 1.0) is a modular instrument measuring patient reported outcomes and is composed of 17 independent scales with promising psychometric properties. Respondents rate their symptom burden during the past seven days using a dichotomous response or 4 point rating scale. Each scale provides coverage of a different symptom domain and returns a summed raw score that can be transformed to a linear (0-100) score. Higher scores represent higher symptom burden. After rating scale refinement and item reduction, all scales satisfied the Rasch model requirements for unidimensionality (principal component analysis of residuals: first residual contrast values <2.00 eigenvalue units) and item fit (outfit mean square values within 0.5 -1.5 logits). Rating scale categories were ordered with acceptable category fit statistics (outfit mean square values <2.0 logits). 14 item pairs had evidence of local dependency (residual correlation values >0.4). Across the 17 scales, person reliability ranged from 0.34 to 0.87, person separation ranged from 0.71 to 2.56, item separation ranged from 1.34 to 13.86, and internal consistency reliability (Cronbach’s alpha) ranged from 0.56 to 0.91. CONCLUSIONS: SBQ-LC (version 1.0) is a comprehensive patient reported outcome instrument developed using modern psychometric methods. It measures symptoms of long covid important to people with lived experience of the condition and may be used to evaluate the impact of interventions and inform best practice in clinical management. BMJ Publishing Group Ltd. 2022-04-27 /pmc/articles/PMC9043395/ /pubmed/35477524 http://dx.doi.org/10.1136/bmj-2022-070230 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Hughes, Sarah E
Haroon, Shamil
Subramanian, Anuradhaa
McMullan, Christel
Aiyegbusi, Olalekan L
Turner, Grace M
Jackson, Louise
Davies, Elin Haf
Frost, Chris
McNamara, Gary
Price, Gary
Matthews, Karen
Camaradou, Jennifer
Ormerod, Jane
Walker, Anita
Calvert, Melanie J
Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis
title Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis
title_full Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis
title_fullStr Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis
title_full_unstemmed Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis
title_short Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis
title_sort development and validation of the symptom burden questionnaire for long covid (sbq-lc): rasch analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043395/
https://www.ncbi.nlm.nih.gov/pubmed/35477524
http://dx.doi.org/10.1136/bmj-2022-070230
work_keys_str_mv AT hughessarahe developmentandvalidationofthesymptomburdenquestionnaireforlongcovidsbqlcraschanalysis
AT haroonshamil developmentandvalidationofthesymptomburdenquestionnaireforlongcovidsbqlcraschanalysis
AT subramaniananuradhaa developmentandvalidationofthesymptomburdenquestionnaireforlongcovidsbqlcraschanalysis
AT mcmullanchristel developmentandvalidationofthesymptomburdenquestionnaireforlongcovidsbqlcraschanalysis
AT aiyegbusiolalekanl developmentandvalidationofthesymptomburdenquestionnaireforlongcovidsbqlcraschanalysis
AT turnergracem developmentandvalidationofthesymptomburdenquestionnaireforlongcovidsbqlcraschanalysis
AT jacksonlouise developmentandvalidationofthesymptomburdenquestionnaireforlongcovidsbqlcraschanalysis
AT davieselinhaf developmentandvalidationofthesymptomburdenquestionnaireforlongcovidsbqlcraschanalysis
AT frostchris developmentandvalidationofthesymptomburdenquestionnaireforlongcovidsbqlcraschanalysis
AT mcnamaragary developmentandvalidationofthesymptomburdenquestionnaireforlongcovidsbqlcraschanalysis
AT pricegary developmentandvalidationofthesymptomburdenquestionnaireforlongcovidsbqlcraschanalysis
AT matthewskaren developmentandvalidationofthesymptomburdenquestionnaireforlongcovidsbqlcraschanalysis
AT camaradoujennifer developmentandvalidationofthesymptomburdenquestionnaireforlongcovidsbqlcraschanalysis
AT ormerodjane developmentandvalidationofthesymptomburdenquestionnaireforlongcovidsbqlcraschanalysis
AT walkeranita developmentandvalidationofthesymptomburdenquestionnaireforlongcovidsbqlcraschanalysis
AT calvertmelaniej developmentandvalidationofthesymptomburdenquestionnaireforlongcovidsbqlcraschanalysis